Last reviewed 2026-06-02 · How we verify

Qudexy XR

Upsher-Smith Laboratories · FDA-approved active Small molecule Under review

Qudexy XR is a Anticonvulsant / Antiepileptic agent Small molecule drug developed by Upsher-Smith Laboratories. It is currently FDA-approved for Epilepsy (seizure prophylaxis), Migraine prophylaxis.

Qudexy XR is an extended-release formulation of topiramate that enhances GABAergic inhibition and blocks sodium channels in the central nervous system to reduce neuronal excitability.

Qudexy XR is a small molecule medication used to study various conditions, including Migraine Disorders, Obesity, Uric Acid Stones, Type 2 Diabetes Mellitus in Obese, and Pre-Diabetes. It has been evaluated in clinical trials for the prevention of migraine in children 6 to 11 years old.

At a glance

Generic name	Qudexy XR
Sponsor	Upsher-Smith Laboratories
Drug class	Anticonvulsant / Antiepileptic agent
Target	GABA-A receptor; voltage-gated sodium channels
Modality	Small molecule
Therapeutic area	Neurology
Phase	FDA-approved

Mechanism of action

Topiramate is a sulfamate-substituted monosaccharide that potentiates GABA activity at GABA-A receptors and blocks voltage-gated sodium channels, reducing repetitive neuronal firing. The extended-release formulation allows once-daily dosing while maintaining steady-state plasma concentrations. These dual mechanisms make it effective for seizure suppression and migraine prophylaxis.

Approved indications

Epilepsy (seizure prophylaxis)
Migraine prophylaxis

Common side effects

Cognitive impairment / memory problems
Paresthesia
Weight loss
Fatigue
Dizziness
Acute myopia / angle-closure glaucoma

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Qudexy XR CI brief — competitive landscape report
Qudexy XR updates RSS · CI watch RSS
Upsher-Smith Laboratories portfolio CI

Frequently asked questions about Qudexy XR

What is Qudexy XR?

Qudexy XR is a Anticonvulsant / Antiepileptic agent drug developed by Upsher-Smith Laboratories, indicated for Epilepsy (seizure prophylaxis), Migraine prophylaxis.

How does Qudexy XR work?

Qudexy XR is an extended-release formulation of topiramate that enhances GABAergic inhibition and blocks sodium channels in the central nervous system to reduce neuronal excitability.

What is Qudexy XR used for?

Qudexy XR is indicated for Epilepsy (seizure prophylaxis), Migraine prophylaxis.

Who makes Qudexy XR?

Qudexy XR is developed and marketed by Upsher-Smith Laboratories (see full Upsher-Smith Laboratories pipeline at /company/upsher-smith-laboratories).

What drug class is Qudexy XR in?

Qudexy XR belongs to the Anticonvulsant / Antiepileptic agent class. See all Anticonvulsant / Antiepileptic agent drugs at /class/anticonvulsant-antiepileptic-agent.

What development phase is Qudexy XR in?

Qudexy XR is FDA-approved (marketed).

What are the side effects of Qudexy XR?

Common side effects of Qudexy XR include Cognitive impairment / memory problems, Paresthesia, Weight loss, Fatigue, Dizziness, Acute myopia / angle-closure glaucoma.

What does Qudexy XR target?

Qudexy XR targets GABA-A receptor; voltage-gated sodium channels and is a Anticonvulsant / Antiepileptic agent.

Drug class: All Anticonvulsant / Antiepileptic agent drugs
Target: All drugs targeting GABA-A receptor; voltage-gated sodium channels
Manufacturer: Upsher-Smith Laboratories — full pipeline
Therapeutic area: All drugs in Neurology
Indication: Drugs for Epilepsy (seizure prophylaxis)
Indication: Drugs for Migraine prophylaxis

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing